Tags : Partnership

Baxter and Ayogo Expand their Partnership to Advance Digital Health

Shots: The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure Baxter made an equity investment […]Read More

Amgen Signs a Partnership with Adaptive Biotechnologies to Develop Abs

Shots: Adaptive to expand its platform for selection of B cell receptors of recovered patients from COVID-19. Amgen will utilize its Ab engineering and drug development capabilities to select and develop Abs designed to bind and neutralize SARS-CoV-2. Additionally, Amgen‘s subsidiary DeCODE Genetics located in Iceland, will provide genetic information from patients infected with COVID-19 […]Read More

Xiangxue Signs an Exclusive License Agreement with Athenex to Expand

Shots: Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel, oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories The collaboration represents the expansion of […]Read More

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its

Shots: As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets Following the end of the research period, Kyowa Kirin to get an option to […]Read More

Yas Holding to Acquire Stake in Alvotech and Signs an

Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the […]Read More

Novartis Signs a Multi-Target Agreement with AbCellera for its Ab-Based

Shots: AbCellera to receive technology access fee, funding, milestones, and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets Additionally, AbCellera collaborated with Pfizer, Teva and GSK on 5 Jan,2017, 13 Jun,2017, and on 12 Sept,2017 respectively for its Ab-based technology targeting membrane proteins and collaborated […]Read More